Table 2.
Clinical and Transplant Characteristics According to the Presence of HLA-B Matching.
| HLA-B | HLA-B | P value* | |
|---|---|---|---|
| 0 matching (n = 32) | ≥1 matching (n = 16) | ||
| Female sex, n (%) | 23 (71.9) | 9 (56.2) | 0.279 |
| Age, years | 44.8 ± 8.2 | 38.8 ± 7.6 | 0.019 |
| BMI, kg/m2 | 23.3 ± 2.4 | 24.1 ± 3.1 | 0.339 |
| Duration of diabetes | 28.7 ± 10.8 | 26.0 ± 13.1 | 0.312 |
| Number of donors | 2 (1–3) | 2 (1–3) | 0.297 |
| Infused islet per kg (1,000), IEQ | 12.83 (8.1–16.5) | 12.72 (9.6–15.4) | 0.999 |
| ∆ Time (1st and 2nd infusion), months | 5 (1–8) | 1 (1) | 0.039 |
| ∆ Time (1st and last infusion), months | 20 (15–51) | 33 (22–41) | 0.686 |
| Edmonton-like protocol immunosuppression induction, n (%) | 17 (53.1) | 14 (87.5) | 0.019 |
| T-cell depletion immunosuppression induction, n (%) | 15 (46.9) | 2 (12.5) | 0.019 |
| GLP1 RA and/or DPP4i use, n (%) | 15 (46.9) | 9 (56.2) | 0.540 |
| GAD65 autoantibodies, n (%) | 11 (45.8) | 9 (56.2) | 0.519 |
| IA2 autoantibodies, n (%) | 9 (41.7) | 6 (31.2) | 0.505 |
Data are shown as mean and standard deviation, median and interquartile interval, or percentages. DPP4i: dipeptidyl peptidase 4 inhibitor; GAD65: glutamic acid decarboxylase 65-kilodalton isoform; GLP-1 RA: glucagon-like peptide-1 receptor agonist; HLA: human leukocyte antigen; IA2: islet antigen 2; IEQ: islet equivalent; BMI: body mass index.
*
P value between groups and are according to χ2 test, T-test, or Mann–Whitney U test as appropriate. Italicized values show a significant P value <0.05.